Teva Letrozole Tablet 2.5 mg

Adult dose

○ Adults and older adults: The recommended dose is letrozole 2.5 mg orally once daily, with or without food. If a dose is missed, take it as soon as remembered. However, if it is nearly time for the next dose, skip the missed dose and follow the regular schedule. Do not take a double dose to make up for a missed dose; do not exceed the recommended dose of 2.5 mg. For patients with metastatic disease, continue treatment until cancer progression is confirmed. For adjuvant therapy and extended adjuvant therapy after adjuvant tamoxifen, treatment may be given for 5 years. If cancer recurs during treatment, discontinue the medicine (for extended adjuvant therapy after adjuvant tamoxifen, the optimal duration of treatment associated with long-term administration has not been established.). ○ Patients with hepatic impairment: Blood concentrations of this medicine are slightly increased in patients with moderate hepatic impairment due to cirrhosis, but no dosage adjustment is necessary in patients with mild ～ moderate hepatic impairment. However, if this medicine is used in patients with severe hepatic impairment (Child-Pugh score C), continuous and careful supervision is required. ○ Patients with renal impairment: No dosage adjustment is necessary for patients with renal impairment and creatinine clearance of 10 mL/min or higher.

This drug should not be administered to certain patients. For instance, patients with an allergy to this drug or its components, premenopausal women, those who are pregnant or may become pregnant, and patients with lactose intolerance or genetic lactose-related disorders should not use this drug. Additionally, patients with severely impaired renal function or significant liver dysfunction, those with a history of osteoporosis or at high risk of fractures, women whose menopausal status is uncertain, and patients allergic to certain dyes should use this drug with caution. Due to its effect of lowering estrogen levels, this drug may increase the risk of decreased bone density and osteoporosis, so regular bone density testing is needed if used long-term, along with prevention and treatment of osteoporosis. While taking this drug, symptoms such as hot flashes, joint pain, nausea, fatigue may occur, and various side effects such as hypercholesterolemia, depression, headache, hair loss, skin dryness, vaginal bleeding, etc. may arise. Serious adverse reactions such as thrombosis, heart failure, liver dysfunction, and severe skin reactions may occur, so one should consult a doctor immediately if symptoms arise. Dizziness or drowsiness may occur during driving or operating machinery, so caution is needed. This drug is metabolized in the liver, so the blood concentration may change when used together with drugs that inhibit or induce certain liver metabolic enzymes, thus drug interactions should be monitored. Use during pregnancy may pose risks to the fetus, so women who may become pregnant must ensure adequate contraception, and pregnant or nursing women should not use this drug. The safety and efficacy of this drug in children under 17 years have not been established. In case of overdose, there is no specific antidote, so symptomatic treatment and monitoring of vital signs are necessary. When storing, keep out of reach of children, and store in the original container to prevent quality degradation or misuse.

• urinary tract infection
• pain from neoplasm
• leukopenia
• anaphylactoid reaction
• hypercholesterolemia
• loss of appetite
• increased appetite
• depression
• anxiety
• hypersensitivity

This drug should be stored in a closed container to avoid exposure to air or moisture. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius. Storing it this way will help maintain the drug's efficacy and safety.

Appearance

Dark yellow, convex round film-coated tablet

Package unit

30 tablets (10 tablets/PTP×3)